149 related articles for article (PubMed ID: 36307892)
1. A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy (ARCADE).
van Goor IWJM; Daamen LA; Besselink MG; Bruynzeel AME; Busch OR; Cirkel GA; Groot Koerkamp B; Haj Mohammed N; Heerkens HD; van Laarhoven HWM; Meijer GJ; Nuyttens J; van Santvoort HC; van Tienhoven G; Verkooijen HM; Wilmink JW; Molenaar IQ; Intven MPW;
Trials; 2022 Oct; 23(1):913. PubMed ID: 36307892
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR): a nationwide multicenter randomized controlled trial according to a TwiCs design.
Doppenberg D; Besselink MG; van Eijck CHJ; Intven MPW; Koerkamp BG; Kazemier G; van Laarhoven HWM; Meijerink M; Molenaar IQ; Nuyttens JJME; van Os R; van Santvoort HC; van Tienhoven G; Verkooijen HM; Versteijne E; Wilmink JW; Lagerwaard FJ; Bruynzeel AME;
BMC Cancer; 2022 Dec; 22(1):1363. PubMed ID: 36581914
[TBL] [Abstract][Full Text] [Related]
3. MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC).
Pavic M; Niyazi M; Wilke L; Corradini S; Vornhülz M; Mansmann U; Al Tawil A; Fritsch R; Hörner-Rieber J; Debus J; Guckenberger M; Belka C; Mayerle J; Beyer G
Radiat Oncol; 2022 Jan; 17(1):18. PubMed ID: 35078490
[TBL] [Abstract][Full Text] [Related]
4. Role of stereotactic body radiation in the enhancement of the quality of life in locally advanced pancreatic adenocarcinoma: a systematic review.
Vornhülz M; Anton S; Eross B; Szakács Z; Hegyi P; Regel I; Belka C; Niyazi M; Mayerle J; Beyer G
Radiat Oncol; 2022 Jun; 17(1):108. PubMed ID: 35715808
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage II pancreatic cancer: a prospective, randomized, open-label, single center trial.
Ma T; Bai X; Wei Q; Shui Y; Lao M; Chen W; Huang B; Que R; Gao S; Zhang Y; Chen W; Wang J; Liang T
BMC Cancer; 2022 Aug; 22(1):865. PubMed ID: 35941566
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic body radiotherapy plus rucosopasem in locally advanced or borderline resectable pancreatic cancer: GRECO-2 phase II study design.
Hoffe SE; Aguilera TA; Parikh PJ; Ghaly MM; Herman JM; Caster JM; Kim DW; Costello J; Malafa MP; Moser EC; Kennedy EP; Terry K; Kurman M
Future Oncol; 2024 Mar; 20(8):437-446. PubMed ID: 38264869
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Surgical Resection of Pancreatic Ductal Adenocarcinoma Appears to be Safe and Effective.
Ryan JF; Groot VP; Rosati LM; Hacker-Prietz A; Narang AK; McNutt TR; Jackson JF; Le DT; Jaffee EM; Zheng L; Laheru DA; He J; Pawlik TM; Weiss MJ; Wolfgang CL; Herman JM
Ann Surg Oncol; 2018 Jan; 25(1):280-289. PubMed ID: 29063299
[TBL] [Abstract][Full Text] [Related]
8. Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study.
Comito T; Cozzi L; Zerbi A; Franzese C; Clerici E; Tozzi A; Iftode C; Navarria P; D'Agostino G; Fogliata A; Mancosu P; Tomatis S; Carnaghi C; Personeni N; Santoro A; Scorsetti M
Eur J Surg Oncol; 2017 Apr; 43(4):735-742. PubMed ID: 28131670
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
Zhu X; Cao Y; Liu W; Ju X; Zhao X; Jiang L; Ye Y; Jin G; Zhang H
Lancet Oncol; 2022 Mar; 23(3):e105-e115. PubMed ID: 35240087
[TBL] [Abstract][Full Text] [Related]
10. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
Zhu X; Cao Y; Liu W; Ju X; Zhao X; Jiang L; Ye Y; Jin G; Zhang H
Lancet Oncol; 2021 Aug; 22(8):1093-1102. PubMed ID: 34237249
[TBL] [Abstract][Full Text] [Related]
12. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial.
Hoegen P; Zhang KS; Tonndorf-Martini E; Weykamp F; Regnery S; Naumann P; Lang K; Ristau J; Körber SA; Dreher C; Buchele C; Rippke C; Renkamp CK; Paul KM; König L; Büsch C; Krisam J; Sedlaczek O; Schlemmer HP; Niyazi M; Corradini S; Debus J; Klüter S; Hörner-Rieber J
Radiat Oncol; 2022 Mar; 17(1):59. PubMed ID: 35346270
[TBL] [Abstract][Full Text] [Related]
13. Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabine for locally recurrent pancreatic cancer after surgical resection on survival outcomes: A secondary analysis of an open-label, randomised, controlled, phase 2 trial.
Zhu X; Liu W; Cao Y; Ju X; Zhao X; Jiang L; Ye Y; Zhang H
EClinicalMedicine; 2023 Jan; 55():101764. PubMed ID: 36471691
[TBL] [Abstract][Full Text] [Related]
14. A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol.
Holyoake DL; Ward E; Grose D; McIntosh D; Sebag-Montefiore D; Radhakrishna G; Patel N; Silva M; Mukherjee S; Strauss VY; Odondi L; Fokas E; Melcher A; Hawkins MA
BMC Cancer; 2016 Sep; 16(1):728. PubMed ID: 27619800
[TBL] [Abstract][Full Text] [Related]
15. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1).
Gao S; Zhu X; Shi X; Cao K; Bian Y; Jiang H; Wang K; Guo S; Zhang H; Jin G
Radiat Oncol; 2019 Mar; 14(1):52. PubMed ID: 30917842
[TBL] [Abstract][Full Text] [Related]
16. Proton Radiotherapy for Isolated Local Recurrence of Primary Resected Pancreatic Ductal Adenocarcinoma.
Mizumoto T; Terashima K; Matsuo Y; Nagano F; Demizu Y; Mima M; Sulaiman NS; Tokumaru S; Okimoto T; Toyama H; Fukumoto T
Ann Surg Oncol; 2019 Aug; 26(8):2587-2594. PubMed ID: 31147994
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer: A Systematic Review and Pooled Analysis of 19 Trials.
Petrelli F; Comito T; Ghidini A; Torri V; Scorsetti M; Barni S
Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):313-322. PubMed ID: 28068239
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Reirradiation with Stereotactic Body Radiation Therapy for Locally Recurrent Pancreatic Adenocarcinoma.
Reddy AV; Hill CS; Sehgal S; He J; Zheng L; Herman JM; Meyer J; Narang AK
Clin Oncol (R Coll Radiol); 2022 Jun; 34(6):386-394. PubMed ID: 34974972
[TBL] [Abstract][Full Text] [Related]
19. Assessing local progression after stereotactic body radiation therapy for unresectable pancreatic adenocarcinoma: CT versus PET.
Toesca DAS; Pollom EL; Poullos PD; Flynt L; Cui Y; Quon A; von Eyben R; Koong AC; Chang DT
Pract Radiat Oncol; 2017; 7(2):120-125. PubMed ID: 28274396
[TBL] [Abstract][Full Text] [Related]
20. A safety study of intraoperative radiation therapy following stereotactic body radiation therapy and multi-agent chemotherapy in the treatment of localized pancreatic adenocarcinoma: study protocol of a phase I trial.
Reddy AV; Hill CS; Zheng L; He J; Narang AK
Radiat Oncol; 2022 Oct; 17(1):173. PubMed ID: 36307845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
